Trial intelligence / Profile preview

Capecitabine versus sorafenib sequencing with crossover in advanced hepatocellular carcinoma

2016-003502-13Phase 3Terminated

Sponsor: Sant'Orsola-Malpighi University Hospital
Start: Jun 2021
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of capecitabine and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall survival at 1 year. Started Jun 2021; status: terminated.

Drugs

capecitabinesorafenib

Conditions

hepatocellular carcinoma (HCC)

Beyond the preview

Go deeper on 2016-003502-13.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-003502-13.